INNOVA CAPTABInnova Captab LimitedNSE:INNOVACAPTechnicalAnalystSucritInnova Captab Ltd. (CMP ₹734.65, NSE: INNOVACAP) A fast‑growing pharmaceutical company, incorporated in 2006, headquartered in Himachal Pradesh. Innova Captab operates across contract manufacturing, branded formulations, and exports, with a strong presence in domestic and international markets. Promoter Holding (Dec 2025): Founding group — majority stake --- FY22–FY26 Snapshot - Revenue Growth: Q3 FY26 revenue ₹4,502.93 million (+~20% YoY). → Good - Net Profit: Q3 FY26 PAT ₹421.49 million, strong profitability. → Good - Operating Margin: Profit before tax ₹556.77 million, margin expansion visible. → Good - Equity Capital: Stable post listing. → Good - Dividend Policy: Interim dividend of ₹2 per share declared (Jan 2026). → Good - Asset Building: Expansion in manufacturing facilities and product portfolio. → Good - Sales: FY26 run‑rate indicates >₹18,000 Cr annualized revenue. → Good - Expense: Input cost pressures manageable, efficiency gains offset. → Neutral - EPS: TTM EPS ~₹23.1, reflecting strong earnings. → Good --- Institutional Interest & Ownership Trends (Dec 2025) - Promoter Holding: Majority stake retained. - FII Holding: Growing interest post IPO. - DII Holding: Stable participation. - Retail & Others: Active trading volumes (~80,000 shares/day). --- Strategic Moves & Innovations - Expansion in contract manufacturing and branded formulations. - Investments in new therapeutic segments. - Focus on export markets and regulatory approvals. - Strengthening R&D capabilities. --- Cash Flow & Balance Sheet Strength - Strong operating cash flows supported by rising sales. - Debt levels moderate, balance sheet conservative. - Dividend payout signals confidence in financial strength. --- Risk Factors - Dependence on regulatory approvals and compliance. - Exposure to raw material price volatility. - Competition from domestic/global pharma players. - Execution risks in scaling exports. --- Investor Takeaway Innova Captab has delivered robust revenue growth, margin expansion, and shareholder rewards via dividend, supported by strong promoter control and conservative balance sheet. With ongoing investments in manufacturing and exports, the company is well‑positioned for long‑term growth. Investors should monitor regulatory risks and input costs, but the outlook remains positive for long‑term holders.